What is Wedbush’s Estimate for STOK FY2029 Earnings?

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Wedbush issued their FY2029 earnings per share estimates for Stoke Therapeutics in a note issued to investors on Tuesday, January 7th. Wedbush analyst L. Chico anticipates that the company will post earnings per share of ($0.41) for the year. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.03) per share.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The company had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $3.46 million.

STOK has been the topic of a number of other research reports. Leerink Partners initiated coverage on Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 price target on the stock. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday. Chardan Capital initiated coverage on shares of Stoke Therapeutics in a report on Friday, December 20th. They set a “buy” rating and a $24.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Stoke Therapeutics presently has a consensus rating of “Buy” and an average target price of $21.29.

Stoke Therapeutics Trading Down 3.8 %

STOK stock opened at $8.96 on Thursday. Stoke Therapeutics has a 1-year low of $4.09 and a 1-year high of $17.58. The firm has a market cap of $474.58 million, a PE ratio of -4.27 and a beta of 0.95. The business’s 50-day moving average price is $11.98 and its two-hundred day moving average price is $13.08.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Exome Asset Management LLC acquired a new stake in Stoke Therapeutics during the 3rd quarter valued at $2,170,000. Barclays PLC lifted its stake in shares of Stoke Therapeutics by 145.3% during the 3rd quarter. Barclays PLC now owns 79,740 shares of the company’s stock worth $980,000 after buying an additional 47,239 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Stoke Therapeutics by 9.7% during the 3rd quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock worth $10,705,000 after buying an additional 76,661 shares during the period. Jane Street Group LLC boosted its holdings in shares of Stoke Therapeutics by 338.2% during the 3rd quarter. Jane Street Group LLC now owns 330,442 shares of the company’s stock worth $4,061,000 after buying an additional 255,028 shares during the period. Finally, State Street Corp grew its stake in Stoke Therapeutics by 8.6% in the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock valued at $21,248,000 after buying an additional 137,145 shares during the last quarter.

Insider Activity

In other Stoke Therapeutics news, insider Barry Ticho sold 2,586 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $12.99, for a total transaction of $33,592.14. Following the transaction, the insider now owns 44,746 shares of the company’s stock, valued at $581,250.54. The trade was a 5.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Edward M. Md Kaye sold 6,170 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $78,852.60. Following the completion of the sale, the chief executive officer now directly owns 68,671 shares of the company’s stock, valued at approximately $877,615.38. The trade was a 8.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 62,849 shares of company stock worth $809,421 in the last quarter. Corporate insiders own 11.30% of the company’s stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.